Chapter 31 • Can be targeted either physically or via promoter expression and is nontoxic, noninflammatory, and nonimmunogenic • Should have the potential to incorporate a large transgene and result in high levels of both transduction and transgene expression • Duration of transgene expression and/or genomic integration ought to be regulatable 1. What toxicity issue has been observed with retroviral vectors?
Gene Therapy in Oncology
Summary of Key Points
Recent Advances in Gene Therapy
Ideal Vector Attributes
